Edgen Stock·Sep 20 2025, 07:10戻る
戻る
Incyte's Opzelura Gains Expanded FDA Approval for Pediatric Atopic Dermatitis
Edgen Stock·Sep 20 2025, 07:10
[1] Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis[2] Opzelura's Pediatric Expansion: A Catalyst for Long-Term Growth in Dermatology - AInvest[3] Incyte's Opzelura Gets FDA Nod for Pediatric AD: A Game-Changer in Dermatology's High-Stakes Market - AInvest